№ lp_1_24560
File format: docx
Character count: 39275
File size: 90 KB
The document outlines the procedures and requirements for the official recognition of BSE risk status by the OIE, including necessary risk assessments, legislative and veterinary system evaluations, and surveillance measures.
Note:
Year
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
N/A
Region / city:
N/A
Subject:
Bovine Spongiform Encephalopathy (BSE) Risk Assessment
Document type:
Draft guidelines
Organization / institution:
OIE
Author:
N/A
Target audience:
OIE Member Countries
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Note:
Year
Year:
2022
Region / city:
Paris
Topic:
Antimicrobial use in aquaculture
Document type:
Meeting report
Organization:
World Organisation for Animal Health (OIE)
Author:
Dr. Dante Mateo, Dr. Ólafur Valsson, Dr. Donald Prater, Dr. Siow Foong Chang
Target audience:
OIE members, veterinary professionals, stakeholders in aquaculture
Period of validity:
February 2022
Approval date:
9 February 2022
Date of amendments:
None
Year:
N/A
Region / city:
N/A
Subject:
Bovine Spongiform Encephalopathy (BSE) Risk Assessment
Document type:
Draft guidelines
Organization / institution:
OIE
Author:
N/A
Target audience:
OIE Member Countries
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Year:
2019
Region / City:
Paris
Subject:
Aquatic Animal Health Standards
Document Type:
Meeting Report
Organization:
OIE
Author:
OIE Aquatic Animal Health Standards Commission
Target Audience:
OIE Members
Period of Validity:
N/A
Approval Date:
2 October 2019
Date of Changes:
N/A
Note:
Year
Theme:
Veterinary, Disease Control
Document Type:
Official OIE Recognition Application
Organ / institution:
OIE
Target audience:
Veterinary authorities, policy makers
Year:
N/A
Region / city:
N/A
Subject:
Bovine Spongiform Encephalopathy (BSE) Risk Assessment
Document type:
Draft guidelines
Organization / institution:
OIE
Author:
N/A
Target audience:
OIE Member Countries
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Note:
Year
Year:
2025
Region / City:
Tirana, Albania
Topic:
Neurology, Stroke Mimic, Wernicke Encephalopathy
Document Type:
Case Report
Organization / Institution:
University Hospital Center Mother Teresa
Author:
Roçi E, Mara E, Dodaj S, Vyshka G
Target Audience:
Medical professionals, neurologists, clinicians
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Author:
Nik Heijmink
Student number:
6706541
Date:
12/08/2024
Type of document:
Writing assignment
Academic program:
Neuroscience and Cognition master program, Experimental and Clinical Neuroscience track
Institution:
University Medical Centre Utrecht
Department:
Department for Developmental Origins of Disease, Division Woman and Baby, Brain Center
City:
Utrecht
Country:
The Netherlands
Daily supervision:
M.J.V. Brandt, PhD
Examiner:
C.H.A. Nijboer, Associate Professor
Secondary examiner:
R.J. Pasterkamp, Full Professor
Main topic:
Hypoxic-ischemic encephalopathy and mesenchymal stem cell-derived extracellular vesicles
Key subjects:
Neuroinflammation, neurogenesis, hypothermia treatment, microglia, subventricular zone, exosomes
Year:
2019
Region / city:
London
Theme:
Chronic Hepatic Encephalopathy, Shared Care, Prescribing Guidelines
Document type:
Guideline
Organization / institution:
St George’s University Hospitals NHS Foundation Trust, NHS Croydon, NHS Kingston, NHS Merton, NHS Richmond, NHS Sutton, NHS Wandsworth
Author:
Dr. Sarah Clark, Dr. Tony Brzezicki, Dr. Vinodh Kumar, et al.
Target audience:
General Practitioners, Hospital Consultants, Healthcare Professionals
Effective period:
From December 30, 2019
Approval date:
January 23, 2020
Review date:
December 30, 2021
Date of changes:
July 12, 2019, September 26, 2019, October 4, 2019
Year:
2016
Region / city:
Australia
Topic:
Pharmaceutical utilisation / hepatic encephalopathy
Document type:
Analytical report
Organization / institution:
Drug Utilisation Sub-Committee (DUSC), Department of Human Services (DHS)
Author:
DUSC
Target audience:
Healthcare policymakers, clinicians
Period covered:
December 2013 – March 2016
Date of listing:
1 December 2013
Drug:
Rifaximin
Indication:
Prevention of hepatic encephalopathy recurrence
Dosage:
550 mg twice daily
Treatment requirements:
Combination with lactulose if tolerated; prior episodes of HE required
Regulatory authority:
Therapeutic Goods Administration (TGA)
PBS restriction:
Specialist treatment only; telephone authority approval required
Study type:
Retrospective utilisation analysis
Key findings:
Patient numbers higher than predicted; prescriptions per patient lower than estimated; expenditure aligned with second-year projections
Year:
2021
Region / City:
Kyiv, Ukraine
Field:
Medical Research
Document Type:
Clinical Study
Organization:
Bogomolets National Medical University, Taras Shevchenko National University of Kyiv
Authors:
Elina Manzhalii, Valentyna Moyseyenko, Vitalii Kondratiuk, Nataliia Molochek, Tetyana Falalyeyeva, Nazarii Kobyliak
Target Audience:
Medical professionals, researchers in gastroenterology and hepatology
Duration:
January 2017 - March 2020
Approval Date:
February 22, 2022
Date of Last Revision:
August 1, 2021
Year:
2018
Region / City:
Kent and Medway, UK
Topic:
Hepatic Encephalopathy treatment
Document Type:
Letter
Organization / Institution:
NHS Kent and Medway
Author:
Primary Care Prescriber
Target Audience:
Specialist prescriber
Medication:
Rifaximin (Targaxan)
Shared Care Protocol Reference:
NHS Kent and Medway shared care protocol
Reason for Refusal:
Lack of clinical confidence, protocol not received, patient not optimised, minimum supply not met, medicine not suitable for shared care, other clinical reasons
Patient Information Included:
Name, NHS Number, Date of Birth/Address
Date of Document:
[insert date]
Year:
2026
Field:
Neuroscience / Epilepsy
Document type:
Interview / Research Transcript
Institution:
Department of Anesthesiology
Author:
Manoj Patel, PhD
Target audience:
Researchers, medical professionals, students
Research focus:
SCN8A epileptic encephalopathy, neuronal models, gene therapy
Methods:
Base editing, patient-derived neuronal cultures
Patient relevance:
Pediatric epilepsy
Scientific impact:
Understanding cellular mechanisms of seizure generation
Journal:
World Journal of Gastroenterology
Type of document:
Scientific article
Article type:
Original article; Observational study
Field:
Gastroenterology; Hepatology
Topic:
Cirrhosis; Hepatic encephalopathy; Patient readmission; Mortality risk
Authors:
Xiao-Peng Hu; Jian Gao
Author affiliation:
Second Clinical College, Chongqing Medical University, Chongqing, China; Department of Gastroenterology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Corresponding author:
Jian Gao
Corresponding author position:
Professor; Chief Doctor
Institution:
Second Affiliated Hospital, Chongqing Medical University
City:
Chongqing
Country:
China
Ethics approval:
Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University (No. 2017-064)
Study design:
Observational study
Study period:
January–February 2018
Follow-up period:
6 months
Sample size:
213 patients with cirrhosis
Main variables:
International normalized ratio (INR); Model for End-stage Liver Disease (MELD) score; Hemoglobin level
Primary outcomes:
Early readmission; Mid-term mortality
Received:
April 8, 2019
First decision:
April 30, 2019
Revised:
May 7, 2019
Accepted:
June 8, 2019
Published online:
July 14, 2019
DOI:
10.3748/wjg.v25.i26.3426
License:
Creative Commons Attribution Non Commercial (CC BY-NC 4.0)
Year:
2023
Journal:
World Journal of Gastroenterology
Manuscript Number:
82876
Type:
Mini Review
Authors:
Giuseppe Marrone, Amato Serra, Luca Miele, Marco Biolato, Antonio Liguori, Antonio Grieco, Antonio Gasbarrini
Affiliation:
Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Corresponding Author:
Giuseppe Marrone, MD, PhD
Received Date:
December 28, 2022
Revised Date:
January 24, 2023
Accepted Date:
April 20, 2023
Published Online:
May 21, 2023
Keywords:
Branched-chain amino acids, Hepatic encephalopathy, Sarcopenia, Liver cirrhosis
Focus:
Review of clinical evidence for BCAAs supplementation in cirrhosis-related complications
Patient Population:
Individuals with liver cirrhosis
Complications Discussed:
Hepatic encephalopathy, Sarcopenia
Treatment Approaches:
BCAAs supplementation, non-absorbable disaccharides, antibiotics, supportive therapies
Evidence Type:
Literature review of clinical studies and guidelines
Year:
2019
Region / City:
Belo Horizonte, Minas Gerais, Brazil
Topic:
Hepatic encephalopathy, liver disease, preclinical research
Document type:
Minireview
Institution:
Universidade Federal de Minas Gerais (UFMG)
Authors:
Luiza Cioglia Dias Lima, Aline Silva Miranda, Rodrigo Novaes Ferreira, Milene Alvarenga Rachid, Ana Cristina Simões e Silva
Target audience:
Researchers and clinicians in hepatology and neuroscience
Received:
August 29, 2018
Peer-review started:
August 29, 2018
First decision:
October 16, 2018
Revised:
November 19, 2018
Accepted:
January 28, 2019
Published online:
February 27, 2019
Open Access:
Yes, CC BY-NC 4.0
Manuscript source:
Invited manuscript
Corresponding author:
Ana Cristina Simões e Silva, MD, PhD